You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is A morbidly obese diabetic woman was on failed metformin therapy. She has the history of pancreatitis and family history of bladder cancer. Patient does not want to take injections. Which of the following would be suitable to reduce her glucose levels? and explain in detail?
Ans. C. Canagliflozin Canagliflozin is a Sodium-Glucose Co-Transpoer 2 Inhibitor, given orally and reduces body weight. For the given clinical scenario, Canagliflozin is the preferred drug, as Sitagliptin increases the risk of acute pancreatitis, use of pioglitazone is associated with a small increased risk of bladder cancer and Liraglutide is given subcutaneously.